论文部分内容阅读
最近,美国加州大学洛杉矶分校Jonsson综合癌症中心的研究者发现,溶瘤病毒联合PD-1抑制剂免疫治疗可大幅提升癌症响应率。研究结果发表在《Cell》杂志。这项由美国、瑞士、西班牙、澳大利亚四国科学家进行的晚期黑色素瘤患者Ib期临床试验,结果大大超出预期。研究人员先是向黑色素瘤局部注射溶瘤病毒,破坏肿瘤微环境,然后全身系统性静脉应用PD-1抑制剂,激活和增强T细胞对肿瘤细胞的攻击和杀伤。
Recently, researchers at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles found that oncolytic virus combined with PD-1 inhibitor immunotherapy can dramatically increase cancer response rates. The study was published in “Cell” magazine. The Phase Ib clinical trial of patients with advanced melanoma, conducted by scientists from the United States, Switzerland, Spain and Australia, far exceeded expectations. Researchers first injected oncolytic viruses into melanoma, destroying the tumor microenvironment, and then systemic systemic intravenous PD-1 inhibitors to activate and enhance the T cell attack and killing of tumor cells.